Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study

Authors
Kim, N. H.Choi, J.Choi, K. M.Baik, S. H.Lee, J.Kim, S. G.
Issue Date
9월-2018
Publisher
MASSON EDITEUR
Keywords
Diabetic retinopathy; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes
Citation
DIABETES & METABOLISM, v.44, no.4, pp.361 - 367
Indexed
SCIE
SCOPUS
Journal Title
DIABETES & METABOLISM
Volume
44
Number
4
Start Page
361
End Page
367
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/73680
DOI
10.1016/j.diabet.2018.03.004
ISSN
1262-3636
Abstract
Aims. - This study examined whether dipeptidyl peptidase (DPP)-4 inhibitor use is beneficial or harmful to diabetic retinopathy (DR) compared with other glucose-lowering agents in patients with type 2 diabetes (T2D). Methods. - From a population-based cohort provided by the National Health Insurance Service in Korea, 67,743 adults with T2D were identified as having been treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was performed for two groups comparing ever-use (cases) and never-use (controls) of DPP-4 inhibitors (n = 14,522 in each group). Cox regression analyses were used to assess risk of the following DR events: vitreous haemorrhage; vitrectomy or photocoagulation; intravitreal agent use; and blindness. Results. - During a median follow-up of 28.4 (14.0-45.2) months, there were 305 (in controls) and 342 (in cases) composite DR events. DPP-4 inhibitor ever-use was not associated with overall risk of composite DR events [adjusted hazard ratio (HR): 1.08, 95% CI: 0.93-1.261 compared with never-use, nor was the risk of each DR outcome increased with DPP-4 inhibitor therapy either. However, DPP-4 inhibitor administration for < 12 months was associated with a greater risk of composite DR events (adjusted HR: 1.31, 95% CI: 1.09-1.57) compared with other glucose-lowering agents over the same treatment period. Conclusion. - In comparison to other oral glucose-lowering agents, DPP-4 inhibitor treatment did not increase overall risk of DR. However, DPP-4 inhibitors may be associated with an increased risk of retinopathy events early in the treatment phase. (C) 2018 Elsevier Masson SAS. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Sin Gon photo

Kim, Sin Gon
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE